Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen-Cilag International
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.
After a few false starts, it seems that the EU regulator has begun preparing the ground for a review of Russia’s adenovirus-based COVID-19 vaccine.
CureVac has submitted the pre-clinical data package for its COVID-19 vaccine to the European Medicines Agency, which will be reviewing the data on a rolling basis.
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.